As filed with the Securities and Exchange Commission on August 9, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
AVIDITY BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 46-1336960 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
10578 Science Center Drive, Suite 125
San Diego, California 92121
(858) 401-7900
(Address of Principal Executive Offices)
AVIDITY BIOSCIENCES, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN
(Full Title of the Plan)
Sarah Boyce
President and Chief Executive Officer
Avidity Biosciences, Inc.
10578 Science Center Drive, Suite 125
San Diego, California 92121
(858) 401-7900
(Name, Address and Telephone Number, Including Area Code, of Agent for Service)
Copies to:
Cheston J. Larson
Matthew T. Bush
Latham & Watkins LLP
12670 High Bluff Drive
San Diego, California 92130
(858) 523-5400
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This registration statement registers the offer and sale of an additional 3,000,000 shares of common stock, par value $0.0001 per share, of Avidity Biosciences, Inc. for issuance under the 2022 Employment Inducement Incentive Award Plan (the 2022 Plan). In accordance with Instruction E to Form S-8, the contents of the prior registration statement on Form S-8, File No. 333-268933, filed with the Securities and Exchange Commission (SEC) on December 21, 2022, previously filed with respect to the 2022 Plan, is hereby incorporated by reference herein.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents containing the information specified in Part I of Form S-8 will be sent or given to participants in the 2022 Plan as specified by Rule 428(b)(1) of the Securities Act. These documents and the documents incorporated by reference into this registration statement pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
In this registration statement, Avidity Biosciences, Inc. is sometimes referred to as registrant, we, us or our.
Item 3. Incorporation of Documents by Reference.
The Securities and Exchange Commission (SEC) allows us to incorporate by reference certain information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this registration statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this registration statement the following documents previously filed with the SEC:
| our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 28, 2024, which contains our audited financial statements for the latest fiscal year for which such statements have been filed; |
| our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, filed with the SEC on May 9, 2024 and August 9, 2024, respectively; |
| the information specifically incorporated by reference into our Annual Report on Form 10-K from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 26, 2024, as supplemented by our Proxy Statement Supplement, filed with the SEC on May 15, 2024; |
| our Current Reports on Form 8-K filed with the SEC on January 5, 2024, February 29, 2024, March 4, 2024, May 15, 2024, June 12, 2024, June 14, 2024; June 14, 2024 and August 9, 2024; and |
| the description of our Common Stock set forth in our registration statement on Form 8-A, filed with the SEC on June 9, 2020, as updated by Exhibit 4.3 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021, and any amendment or report filed for the purpose of updating the description. |
In addition, all documents filed by the registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the filing of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement contained herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in any subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.
Under no circumstances shall any information furnished under Items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides for such incorporation by reference.
Item 8. Exhibits.
Exhibit Number |
Incorporated by Reference |
Filed | ||||||||||
Exhibit Description |
Form |
File No. |
Exhibit |
Filing Date | ||||||||
3.1 |
Amended and Restated Certificate of Incorporation | 8-K | 001-39321 | 3.1 | 6/16/2020 | |||||||
3.2 |
Amended and Restated Bylaws | 8-K | 001-39321 | 3.1 | 12/13/2023 | |||||||
4.1 |
Form of Common Stock Certificate | S-1 | 333-238612 | 4.1 | 5/22/2020 | |||||||
5.1 |
Opinion of Latham & Watkins LLP | X | ||||||||||
10.1 |
Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan, including form of stock option grant notice and stock option agreement and form of restricted stock unit grant notice and restricted stock unit agreement thereunder | 10-K | 001-39321 | 10.5 | 2/28/2023 | |||||||
10.2 |
Amendment to the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan | 8-K | 001-39321 | 10.1 | 6/12/2024 | |||||||
23.1 |
Consent of BDO USA, P.C., independent registered public accounting firm | X | ||||||||||
23.2 |
Consent of Latham & Watkins LLP (included in Exhibit 5.1 hereto) | X | ||||||||||
24.1 |
Power of Attorney (see signature page) | X | ||||||||||
107 |
Filing Fee Table | X |
Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that the registrant meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 9, 2024.
AVIDITY BIOSCIENCES, INC. | ||
By: | /s/ Sarah Boyce | |
Sarah Boyce President and Chief Executive Officer |
Each person whose signature appears below hereby constitutes and appoints Sarah Boyce and Michael F. MacLean, jointly and severally, his or her attorneys-in-fact, each with the full power of substitution, for him or her in any and all capacities, to sign this registration statement, and any amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act, this registration statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ Sarah Boyce Sarah Boyce |
President, Chief Executive Officer and Director (Principal Executive Officer) |
August 9, 2024 | ||
/s/Michael F. MacLean Michael F. MacLean |
Chief Financial and Chief Business Officer (Principal Financial and Accounting Officer) |
August 9, 2024 | ||
/s/ Troy Wilson, Ph.D., J.D. Troy Wilson, Ph.D., J.D. |
Chair of the Board of Directors |
August 9, 2024 | ||
/s/ Carsten Boess Carsten Boess |
Director | August 9, 2024 | ||
/s/ Noreen Henig, M.D. Noreen Henig, M.D. |
Director | August 9, 2024 | ||
/s/ Edward Kaye, M.D. Edward Kaye, M.D. |
Director | August 9, 2024 | ||
/s/ Jean Kim Jean Kim |
Director | August 9, 2024 | ||
/s/ Arthur A. Levin, Ph.D. Arthur A. Levin, Ph.D. |
Director | August 9, 2024 | ||
/s/ Simona Skerjanec Simona Skerjanec |
Director | August 9, 2024 | ||
/s/ Tamar Thompson Tamar Thompson |
Director | August 9, 2024 |
Exhibit 5.1
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com | ||||||||||||||
|
FIRM / AFFILIATE OFFICES | |||||||||||||
Austin |
Milan |
| ||||||||||||
Beijing |
Munich |
|||||||||||||
Boston |
New York |
|||||||||||||
Brussels |
Orange County |
|||||||||||||
Century City |
Paris |
|||||||||||||
Chicago |
Riyadh |
|||||||||||||
Dubai |
San Diego |
|||||||||||||
Düsseldorf |
San Francisco |
|||||||||||||
Frankfurt |
Seoul |
|||||||||||||
Hamburg |
Silicon Valley |
|||||||||||||
Hong Kong |
Singapore |
|||||||||||||
Houston |
Tel Aviv |
|||||||||||||
London |
Tokyo |
|||||||||||||
Los Angeles |
Washington, D.C. |
|||||||||||||
Madrid |
August 9, 2024
Avidity Biosciences, Inc.
10578 Science Center Drive, Suite 125
San Diego, California 92121
Re: Registration Statement on Form S-8; 3,000,000 Shares of Common Stock, par value $0.0001 per share
To the addressees set forth above:
We have acted as special counsel to Avidity Biosciences, Inc., a Delaware corporation (the Company), in connection with the proposed issuance of an aggregate of 3,000,000 shares of common stock, $0.0001 par value per share (the Shares), of the Company, pursuant to the Companys 2022 Employment Inducement Incentive Award Plan (the Plan). The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the Act), filed with the Securities and Exchange Commission (the Commission) on August 9, 2024 (the Registration Statement). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, other than as expressly stated herein with respect to the issue of the Shares.
As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware and we express no opinion with respect to any other laws.
In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity to authentic original documents of all documents submitted to us as copies.
Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the recipients, or certificates representing the Shares (in the form of the specimen certificate most recently filed as an exhibit to the Registration Statement) have been manually signed by an authorized officer of the transfer agent and registrar therefor, and subject to the Company completing all actions and proceedings required on its part to be taken prior to the issuance
August 9, 2024
Page 2
of the Shares, and when the Shares have been issued by the Company in the circumstances contemplated by the Plan for legal consideration in excess of par value, the issuance of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware.
This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.
Sincerely,
/s/ Latham & Watkins LLP
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our reports dated February 28, 2024, relating to the financial statements and the effectiveness of internal control over financial reporting of Avidity Biosciences, Inc. (the Company) appearing in the Companys Annual Report on Form 10-K for the year ended December 31, 2023. Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectiveness of the Companys internal control over financial reporting as of December 31, 2023.
/s/ BDO USA, P.C.
San Diego, California
August 9, 2024
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered (1) |
Proposed Maximum Offering Price Per Share |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee | |||||||
and Rule 457(h) |
(2) |
$ |
$ (3) |
$ | per $1,000,000$ | |||||||||
and Rule 457(h) |
$ |
$ |
$ | per $1,000,000$ | ||||||||||
Total Offering Amounts |
$ |
$ | ||||||||||||
Total Fee Offsets (6) |
$ | |||||||||||||
Net Fee Due |
$ |
(1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also registers an indeterminate number of additional shares that may be issued pursuant to the above-named plans as the result of any future stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. |
(2) | Represents 3,000,000 shares of common stock available for fu tur e issuance under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the “Inducement Plan”). |
(3) | This estimate is made pursuant to Rule 457(c) and 457(h) of the Securities Act solely for purposes of calculating the registration fee. The maximum offering price per share and the maximum aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Select Market on August 5, 2024, which date is within five business days prior to filing this registration statement. |
(4) | Consists of 288,200 shares of common stock subject to outstanding stock options under the Inducement Plan. To the extent that outstanding stock options or other awards under the Inducement Plan are forfeited or lapse unexercised, the shares of common stock subject to such awards will be available for future issuance under the Inducement Plan. |
(5) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based upon the weighted average exercise price of the outstanding stock options granted under the Inducement Plan. |
(6) | The Registrant does not have any fee offsets. |
Submission |
Aug. 09, 2024 |
---|---|
Submission [Line Items] | |
Central Index Key | 0001599901 |
Registrant Name | Avidity Biosciences, Inc. |
Form Type | S-8 |
Submission Type | S-8 |
Fee Exhibit Type | EX-FILING FEES |
Offerings |
Aug. 09, 2024
USD ($)
shares
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Offering: 1 | ||||||||||
Offering: | ||||||||||
Fee Previously Paid | false | |||||||||
Other Rule | true | |||||||||
Security Type | Equity | |||||||||
Security Class Title | Common Stock, $0.0001 par value | |||||||||
Amount Registered | shares | 3,000,000 | |||||||||
Proposed Maximum Offering Price per Unit | 39.7 | |||||||||
Maximum Aggregate Offering Price | $ 119,100,000 | |||||||||
Fee Rate | 0.01476% | |||||||||
Amount of Registration Fee | $ 17,579.16 | |||||||||
Offering Note |
|
|||||||||
Offering: 2 | ||||||||||
Offering: | ||||||||||
Fee Previously Paid | false | |||||||||
Other Rule | true | |||||||||
Security Class Title | Common Stock, $0.0001 par value | |||||||||
Amount Registered | shares | 288,200 | |||||||||
Proposed Maximum Offering Price per Unit | 44.81 | |||||||||
Maximum Aggregate Offering Price | $ 12,914,242 | |||||||||
Fee Rate | 0.01476% | |||||||||
Amount of Registration Fee | $ 1,906.15 | |||||||||
Offering Note |
|
Fees Summary |
Aug. 09, 2024
USD ($)
|
---|---|
Fees Summary [Line Items] | |
Total Offering | $ 132,014,242 |
Total Fee Amount | 19,485.3 |
Total Offset Amount | 0 |
Net Fee | $ 19,485.3 |
O/)#[\,9H_/!Z/P<>_*-*T+1URP#45;YE+L.?V7QID,.
MB3_'GA_@ $?N84(Z&*2#"Z3U2:$5XTVEIL0[AG L?A-<+V;S:>G%(+VXK&JI
M7XW3ZAW)8J3N3>N&@VYX5O>+EM,%3VEU0-__;ZGNJ%?,L_.9B+RL)**0::0W
MN])^1=?*7:!X;=MGQY5N1CLM].L'PB3H_8QS=0Q,1P[O:?(74$L#!!0 (
M #V("5F>>[C ,0, /(2 - >&PO
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